Scrip
Clinica
Scrip Regulatory Affairs
Scrip Clinical Research
AnimalPharm
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Advanced Search
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
News
|
Comment
|
Features
|
Analysis
|
Market Data
|
People
|
Events
|
Multimedia
|
Science Abstracts
|
Gilead's $375 million Calistoga buy signals shift into oncology and inflammation
22 February 2011
Donna Young
Please Login to read the full article.
Not a subscriber?
Subscribe to Scrip
Request a FREE Trial
RELATED CONTENT
NEWS
Scrip News
New Thai govt outlines policies generally positive for industry
Gilenya and Tasigna drive new product growth at Novartis
NICE gives Roche's MabThera final nod for non-Hodgkin's lymphoma
Achillion raising $56.6 million to advance hepatitis C candidates
Other Informa News
Toumaz sets up JV, readies for US launch of wireless patient monitoring "plaster"
Luminex buys EraGen Biosciences; gains new PCR platform
About Us
Getting Started
Subscribe
Free Trial
Advertise
Awards
White Papers
Executive Briefing
Classifieds
Recruitment
JOB OF THE WEEK
Promote your vacancy here
SCRIP's ONLINE DIRECTORY
Classified ads